4//SEC Filing
Walsh Jeffrey T. 4
Accession 0001209191-19-036381
CIK 0001293971other
Filed
Jun 11, 8:00 PM ET
Accepted
Jun 12, 4:31 PM ET
Size
10.7 KB
Accession
0001209191-19-036381
Insider Transaction Report
Form 4
Walsh Jeffrey T.
Chief Operating Officer
Transactions
- Sale
Common Stock
2019-06-10$126.96/sh−200$25,392→ 40,921 total - Exercise/Conversion
Stock Option (right to buy)
2019-06-10−1,400→ 10,121 totalExercise: $24.47Exp: 2024-03-03→ Common Stock (1,400 underlying) - Exercise/Conversion
Common Stock
2019-06-10$24.47/sh+1,400$34,258→ 42,321 total - Sale
Common Stock
2019-06-10$125.19/sh−1,200$150,227→ 41,121 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
- [F2]The range of prices for the transaction reported on this line was $125.00 to $125.55. The average weighted price was $125.1892. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
Documents
Issuer
bluebird bio, Inc.
CIK 0001293971
Entity typeother
Related Parties
1- filerCIK 0001578251
Filing Metadata
- Form type
- 4
- Filed
- Jun 11, 8:00 PM ET
- Accepted
- Jun 12, 4:31 PM ET
- Size
- 10.7 KB